Compare RELL & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | CCCC |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.3M | 185.1M |
| IPO Year | 2004 | 2020 |
| Metric | RELL | CCCC |
|---|---|---|
| Price | $11.09 | $2.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 77.4K | ★ 2.0M |
| Earning Date | 04-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,909,000.00 | $35,947,000.00 |
| Revenue This Year | $5.62 | N/A |
| Revenue Next Year | $13.95 | N/A |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | ★ 6.34 | 1.02 |
| 52 Week Low | $7.57 | $1.09 |
| 52 Week High | $15.34 | $3.82 |
| Indicator | RELL | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 55.49 |
| Support Level | $10.52 | $2.26 |
| Resistance Level | $11.55 | $2.85 |
| Average True Range (ATR) | 0.54 | 0.20 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 44.29 | 89.57 |
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.